Viridian Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Derek Archila from Wells Fargo maintained a Hold rating on the stock and has a $26.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Derek Archila has given his Hold rating due to a combination of factors surrounding Viridian Therapeutics’ current position and future prospects. The company is expected to remain stable in the near term as it awaits significant developments in 2026, particularly concerning its VRDN-003 program. While management has successfully maintained timelines for key projects like veligrotug and VRDN-003, the immediate upside is limited, especially with VRDN-006 Phase 1 data anticipated in the third quarter of 2025.
Despite the company’s solid cash position, which funds operations into the second half of 2027, and the expected launch of veligrotug in 2026, the lack of immediate catalysts in 2025 has contributed to the stock’s underperformance compared to broader indices. The anticipated Phase 3 data for VRDN-003 in the first half of 2026 is seen as a critical factor that could potentially enhance the stock’s outlook, but until then, the stock is likely to remain range-bound.
Archila covers the Healthcare sector, focusing on stocks such as Exelixis, Incyte, and Apellis Pharmaceuticals. According to TipRanks, Archila has an average return of 10.6% and a 51.57% success rate on recommended stocks.
In another report released on July 30, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $17.50 price target.